Treatment of Uveitis in HLA-B27 Positive Patients
For HLA-B27 positive patients with acute anterior uveitis (AAU), initial treatment with topical corticosteroids (prednisolone acetate 1%) plus cycloplegic agents is the standard approach, and systemic therapy should NOT be changed immediately if the patient is already on stable immunosuppression—treat the acute episode topically first. 1
Key Clinical Distinction: Acute vs. Chronic Uveitis
HLA-B27 associated uveitis presents as acute anterior uveitis (AAU)—episodic, unilateral, symptomatic with sudden onset of pain, redness, and photophobia. This differs fundamentally from chronic anterior uveitis (CAU) seen in JIA, which is asymptomatic and bilateral 2, 1.
Initial Management Algorithm
For Acute Episodes:
1. First-line therapy:
- Topical prednisolone acetate 1% (may require 1-2 drops/eye/day initially)
- Cycloplegic agents (to prevent posterior synechiae)
- Refer to ophthalmology within 2 days for grade 2 or higher 3
2. Patient education (STRONGLY recommended):
- Educate all HLA-B27 positive patients with spondyloarthritis about warning signs: eye pain, redness, photophobia
- This decreases delay in treatment and prevents complications 1
For Patients Already on Systemic Immunosuppression:
If the patient is well-controlled on DMARDs or biologics and develops an isolated AAU episode:
- Continue current systemic therapy unchanged
- Treat with topical corticosteroids first
- Do NOT immediately switch or escalate systemic therapy 1
This is because AAU episodes are typically short-lived and easily controlled topically. Only consider changing systemic therapy if there are frequent recurrent episodes or complications from topical steroids.
When to Initiate or Change Systemic Therapy
Indications for systemic treatment:
- Frequent recurrences (>2 flares per year) 4
- Severe uveitis with complications
- Bilateral involvement
- Refractory to topical therapy
- Corticosteroid-induced complications (glaucoma, cataracts)
Systemic Treatment Hierarchy:
First-line systemic agent:
- Sulfasalazine has demonstrated efficacy in reducing AAU recurrence rate (from 2.46 to 0.37 recurrences/year, p<0.001) 4
- This is particularly appropriate when treating for ophthalmologic purposes alone
For refractory cases or when treating concurrent spondyloarthritis:
Monoclonal antibody TNF inhibitors are STRONGLY preferred over other biologics:
- Adalimumab or Infliximab (NOT etanercept, which is less effective for uveitis) 5, 6
- These are recommended over IL-17 inhibitors (secukinumab) or JAK inhibitors for patients with uveitis 5, 6
- Golimumab has shown efficacy with remission in 80% of cases 7
Dosing specifics:
- Adalimumab: Standard dosing every 2 weeks, can escalate to weekly if needed
- Infliximab: 6-10 mg/kg, can escalate to 20 mg/kg every 2 weeks for refractory cases 1
Evidence for TNF inhibitor efficacy:
Studies demonstrate that infliximab induces steroid-free remission in 87.5% of HLA-B27 positive patients with refractory uveitis, with mean treatment duration of 16.5 months to achieve remission 8. Adalimumab and golimumab show similar efficacy 9, 7.
Critical Pitfalls to Avoid
Do NOT use etanercept for uveitis—it has higher AAU recurrence rates compared to monoclonal antibodies 5
Do NOT immediately escalate systemic therapy for an isolated AAU flare in a patient otherwise well-controlled—try topical therapy first 1
Do NOT use IL-17 inhibitors (secukinumab) as first-line for uveitis, especially if concurrent inflammatory bowel disease exists 5
Avoid NSAIDs if inflammatory bowel disease is present, as they can precipitate flares 5
Monitoring Requirements
- Ophthalmology follow-up within 2 days for symptomatic AAU (grade 2+) 3
- Urgent ophthalmology referral for posterior or pan-uveitis (grade 3+) or vision loss 3
- Coordinate all treatment decisions with ophthalmologist, particularly for grade 3+ disease 3
Multidisciplinary Coordination
Strongly recommended collaboration with:
- Ophthalmologist (preferably uveitis specialist for severe cases)
- Rheumatologist (60-92% have associated spondyloarthritis) 10, 9
- Screen for associated conditions: ankylosing spondylitis, reactive arthritis, psoriatic arthritis, inflammatory bowel disease 1, 11
The ophthalmologist often makes the initial diagnosis of systemic disease, as up to 40% of HLA-B27 positive AAU patients have undiagnosed systemic conditions 12.